TITLE

COMMENTARY: Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction

AUTHOR(S)
Borzak, Steven
PUB. DATE
September 2006
SOURCE
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article comments on the study related to the use of the drug fondaparinux to treat patients with acute ST-segment elevation myocardial infarction (STEMI). In the study fondaparinux was found useful in reducing death. These trials support the use of anticoagulant therapy in patients with STEMI. However, the angioplasty patients did not do well with the drug fondaparinux than with low-molecular-weight heparin.
ACCESSION #
22493465

 

Related Articles

  • COMMENTARY: Enoxaparin was more effective than unfractionated heparin in STEMI, regardless of type of fibrinolytic agent used. Bates, Eric R. // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p63 

    The author reflects upon the findings of a study, that investigated the effectiveness of enoxaparin, in comparison with unfractionated heparin (UFH), for patients with ST-elevation myocardial infarction (STEMI). He states that the study suggests the use of anticoagulation for patients until...

  • ANTICOAGULANTS IN ACUTE MI. Santiago, Tamara; Chasuk, Robert // Journal of Family Practice;Jan1997, Vol. 44 Issue 1, p28 

    The article discusses a study on the clinical effect of anticoagulant therapy in the treatment of patients suspected of having an acute myocardial infarction. The study is a type of review article that used quantitative methods in summarizing the results from clinical trials. Studies were...

  • Enoxaparin was more effective than unfractionated heparin in STEMI, regardless of type of fibrinolytic agent used.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p63 

    The article offers information on a study that investigates the effectiveness of enoxaparin, in comparison with unfractionated heparin (UFH), for patients with ST-elevation myocardial infarction (STEMI), irrespective of the type of fibrinolytic agent used. It describes the method and patients'...

  • Can BRIGHT Restore the Glow of Bivalirudin? Cavender, Matthew A.; Faxon, David P. // JAMA: Journal of the American Medical Association;4/7/2015, Vol. 313 Issue 13, p1323 

    The authors focus on the results of the Bivalirudin in Acute Myocardial Infarction Versus Heparin and Glycoprotein IIb/IIIa Inhibitors (GPI) Plus Heparin Trial (BRIGHT) conducted by Y. Han and colleagues. The trial studies direct thrombin inhibitor bivalirudin in patients undergoing percutaneous...

  • Benefits of long-term post-MI anticoagulation outweigh the costs.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p49 

    Presents an abstract of the articles `Costs and effects of long-term oral anticoagulant treatment after myocardial infarction,' by P.F.M. van Bergen, J.J.C. Jonker et al, published in the March 22-29, 1995 issue of the `Journal of the American Medical Association,' and `Economics and efficacy in...

  • Oral anticoagulants--the totem and the taboo. Breckenridge, A. // British Medical Journal;2/21/1976, Vol. 1 Issue 6007, p419 

    Investigates the efficacy of oral anticoagulants. Controversy on the use of anticoagulants in acute myocardial infarction; Conduction of a clinical trial on the effectiveness of anticoagulants; Conclusion that anticoagulants is of no benefits as a treatment to diseases.

  • Prehospital Bivalirudin Improved Outcomes Versus Heparin in Patients With Myocardial Infarction. Rizzo, Toni // MD Conference Express;Dec2013, p18 

    The article discusses the results of the European Ambulance Acute Coronary Syndrome Angiography Trial which examines whether bivalirudin was superior to heparin and provisional use of glycoprotein IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction (STEMI). It states...

  • Revised Guidelines for Acute MI. van Vlaanderen, Edward // Cortlandt Forum;07/25/2000, Vol. 13 Issue 7, p132 

    Presents guidelines in the treatment of myocardial infarction. Evaluation of the effectiveness of angioplasty; Incorporation of new serum cardiac markers; Antithrombotic therapy; Trend toward low-molecular-weight heparin; Use of beta blockers and hormone replacement therapy.

  • Antithrombotic therapy in myocardial infarction and stable angina. Lip, Gregory Y.H.; Chin, Bernard S.P.; Prasad, Neeraj // BMJ: British Medical Journal (International Edition);11/30/2002, Vol. 325 Issue 7375, p1287 

    Discusses the use of antithrombotic therapy in myocardial infarction and stable angina. Thrombolytic treatment; Primary angioplasty; Patients who should be offered thrombolytic treatment; Reperfusion of the artery affected by infarction; Plasminogen activators; Antiplatelet treatment;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics